Keyphrases
Cancer Clinical Trials
100%
Pembrolizumab
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Tribulation
100%
Prostate Cancer Patients
75%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
37%
Programmed Death-ligand 1 (PD-L1)
25%
Molecular Defects
25%
Improved Outcomes
12%
Malignancy
12%
Prostate Cancer
12%
Chemotherapy
12%
PARP Inhibitor (PARPi)
12%
Phase III Clinical Trial
12%
Immune Checkpoint Inhibitors
12%
Immuno-oncology
12%
Mismatch Repair
12%
Expert Opinion
12%
Blocking Antibodies
12%
Genetic Defects
12%
Combination Strategy
12%
Hormonal Agents
12%
Programmed Death-ligand 1 Expression
12%
Area Cover
12%
Therapeutic Combinations
12%
Microsatellite Instability-high (MSI-H)
12%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Pembrolizumab
100%
Prostate Cancer
87%
Programmed Death 1 Ligand 1
25%
Oncology
12%
Clinical Trial
12%
Immunoglobulin
12%
Cancer
12%
PARP Inhibitor
12%
DNA Mismatch Repair
12%
Immunotherapy
12%
Microsatellite Instability
12%
Blocking Antibody
12%
Diseases
12%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Pembrolizumab
100%
Prostate Cancer
87%
Programmed Death 1 Ligand 1
25%
Clinical Trial
12%
Chemotherapy
12%
Immunoglobulin
12%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
12%
Immunotherapy
12%
Blocking Antibody
12%
Diseases
12%